Description:
PF-04971729, a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is developed for the treatment of diabetes mellitus. Inhibitory effects against the organic cation transporter 2-mediated uptake of [14C]metformin by PF-04971729 is very weak (IC50 = 900μM).
- Molecular Weight: 436.88
- Molecular Formula: C22H25ClO7
Purity: >98%
Canonical SMILES:
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C34C(C(C(C(O3)(CO4)CO)O)O)O)Cl
InChI:
InChI=1S/C22H25ClO7/c1-2-28-16-6-3-13(4-7-16)9-14-10-15(5-8-17(14)23)22-20(27)18(25)19(26)21(11-24,30-22)12-29-22/h3-8,10,18-20,24-27H,2,9,11-12H2,1H3/t18-,19-,20+,21-,22-/m0/s1
InChIKey: MCIACXAZCBVDEE-CUUWFGFTSA-N
- Boiling Point: 630.5±55.0°C at 760 mmHg
- Melting Point: 65-66°C
- Solubility: Soluble in DMSO (Sparingly), Methanol (Slightly)
- Appearance: White to Off-white Solid
- Application: Sodium-Glucose Transporter 2 Inhibitors
- Storage: Store at -20°C under inert atmosphere
Synonyms:
PF-04971729; PF 04971729; PF04971729; PF-04971729-00; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose; MK 8835; Steglatro; β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-; 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose; (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
More details are to be found on supplier website
